Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan K Davis

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Journal of Psychedelic Studies|January 23, 2023
Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use DisorderJohn M Clifton, Annabelle M Belcher, Aaron D Greenblatt, et al.
Journal of American College Health : J of ACH|July 22, 2021
What undergraduates want in campus sexual assault prevention programming: Findings from a formative research studyMeredith L Philyaw-Kotov, Maureen A Walton, Brianne Brenneman, et al.
Journal of Substance Use and Addiction Treatment|April 5, 2023
Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and CanadaAngela M Haeny, Joel A Lopez, Pamela A Colón Grigas, et al.
Journal of Psychopharmacology (Oxford, England)|April 30, 2020
Survey of entity encounter experiences occasioned by inhaled <i>N,N</i>-dimethyltryptamine: Phenomenology, interpretation, and enduring effectsAlan K Davis, John M Clifton, Eric G Weaver, et al.
Expert Review of Clinical Pharmacology|June 5, 2025
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugsVictor Pablo Acero, Taylor A Flatt, Peter M Gooch, et al.
Addictive Behaviors|August 1, 2016
Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatmentAlan K Davis, Erin E Bonar, Mark A Ilgen, et al.
Addictive Behaviors|May 4, 2019
Predictors of empirically derived substance use patterns among sexual minority groups presenting at an emergency departmentBrooke J Arterberry, Alan K Davis, Maureen A Walton, et al.
Journal of Neurochemistry|February 12, 2022
The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)Johannes T Reckweg, Malin V Uthaug, Attila Szabo, et al.
Drugs (Abingdon, England)|August 5, 2021
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiencesMonnica T Williams, Alan K Davis, Yitong Xin, et al.
Journal of Psychopharmacology (Oxford, England)|February 15, 2022
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-upNatalie Gukasyan, Alan K Davis, Frederick S Barrett, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Journal of Psychedelic Studies|January 23, 2023
Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use DisorderJohn M Clifton, Annabelle M Belcher, Aaron D Greenblatt, et al.
Journal of American College Health : J of ACH|July 22, 2021
What undergraduates want in campus sexual assault prevention programming: Findings from a formative research studyMeredith L Philyaw-Kotov, Maureen A Walton, Brianne Brenneman, et al.
Journal of Substance Use and Addiction Treatment|April 5, 2023
Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and CanadaAngela M Haeny, Joel A Lopez, Pamela A Colón Grigas, et al.
Journal of Psychopharmacology (Oxford, England)|April 30, 2020
Survey of entity encounter experiences occasioned by inhaled <i>N,N</i>-dimethyltryptamine: Phenomenology, interpretation, and enduring effectsAlan K Davis, John M Clifton, Eric G Weaver, et al.
Expert Review of Clinical Pharmacology|June 5, 2025
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugsVictor Pablo Acero, Taylor A Flatt, Peter M Gooch, et al.
Addictive Behaviors|August 1, 2016
Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatmentAlan K Davis, Erin E Bonar, Mark A Ilgen, et al.
Addictive Behaviors|May 4, 2019
Predictors of empirically derived substance use patterns among sexual minority groups presenting at an emergency departmentBrooke J Arterberry, Alan K Davis, Maureen A Walton, et al.
Journal of Neurochemistry|February 12, 2022
The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)Johannes T Reckweg, Malin V Uthaug, Attila Szabo, et al.
Drugs (Abingdon, England)|August 5, 2021
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiencesMonnica T Williams, Alan K Davis, Yitong Xin, et al.
Journal of Psychopharmacology (Oxford, England)|February 15, 2022
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-upNatalie Gukasyan, Alan K Davis, Frederick S Barrett, et al.
Pageof 10